Product Description
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | India | New Zealand | Norway | Peru | Portugal | Slovenia | Sweden | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Osteoarthritis|Acute Pain|Hypertension|Pain Unspecified|Healthy Volunteers|Musculoskeletal Pain
Phase 3: Osteoarthritis|Arthritis, Rheumatoid|Osteoarthritis, Knee|Osteoarthritis, Hip|Pain Unspecified
Phase 2: Kidney Failure, Chronic|Arthralgia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Pregnancy Outcomes |
2019-12-01 |
|
PEMEX-805415-00-2 | P2 |
Terminated |
Kidney Failure, Chronic|Arthralgia |
2012-11-01 |
|
ND | P4 |
Completed |
Unknown |
2010-10-16 |
|
2005-005949-19 | P3 |
Completed |
Pain Unspecified |
2006-12-15 |